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Over the last decades, major advances in therapeutic strate-
gies for chronic diseases have significantly reduced death
rates. Redox signaling is being implicated in the pathophysi-
ology of such diseases, affecting most organs. Proliferation of
cancer cells, damage to cardiomyocytes and vascular cells,
and exacerbation of inflammation are just a few examples
of events importantly controlled by reacting oxygen species
(ROS). Physiologic levels of ROS act as signaling molecules
and modulate healthy functions, while high levels of ROS
can derange the homeostasis of most organs and systems in
our body. Hence, fine-tuning the complexity of redox signal-
ing is a very up-to-date field of research.
Light-based technologies are emerging as powerful
tools in several experimental and clinical arenas [1, 2].
Two manuscripts in this issue focus on the use of light
to detect and interfere with ROS signaling. In their review,
M. R. Antognazza et al. describe the state-of-the-art and
recent advances in the field of photostimulation of oxidative
stress (from photobiomodulation mediated by naturally
expressed light-sensitive proteins to the latest optogenetic
approaches) and highlight novel concepts based on optically
driven ROS regulations mediated by polymeric materials.
The possibility to modulate oxidative stress in disease
conditions also paves the way to innovative therapeutic inter-
vention. The manuscript by K. Rupel et al. explores the
changes in ROS levels upon photobiomodulation, also known
as laser therapy, an emerging therapeutic option for patients
affected by oral mucositis and other side effects of chemo-
and radiotherapy. The authors have usedmultiple approaches
to measure ROS levels, also including an elegant genetically
encoded sensor, in both clinical samples and cultured cells.
They showed that light variably impacts on intracellular
ROS levels, depending on the used wavelength, prompting
the use of a multiwavelength approach in the clinics.
The crosstalk between reactive oxygen species and NF-κB
(nuclear factor kappa-light-chain-enhancer of activated B
cells) signaling is a consolidated knowledge in cancer devel-
opment and progression. It is involved in crucial cellular
events, such as apoptosis, differentiation, proliferation,
angiogenesis, inflammation, and ROS production [3–13].
J. Gambardella et al. explore the effect of a small peptide able
to mimic the minimum effective sequence of the RH domain
of G protein-coupled receptor kinase 5 (GRK5), thereby inhi-
biting NF-κB activity. This resulted in a potent suppression
of tumor growth both in vitro and in vivo, suggesting a
potential benefit in cancer treatment either alone or in com-
bination with conventional anticancer therapies. In another
interesting cancer study, M. Calvani et al. uncover a novel
mechanism directed by mitochondrial ROS and β3-adreno-
ceptors to suppress the viability of cancer cells. In these cells,
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β3-adrenoceptors have a mitochondrial localization that
enables them to drive mitochondrial dormancy and thus
glycolytic metabolism, a documented proliferative advan-
tage of tumor cells [14]. To lay the basis for this metabolic
shift, β3-adrenoceptors upregulate uncoupling protein 2
(UCP2), reduce mitochondrial ATP and ROS synthesis,
and increase cytoplasmic glycolytic enzymes. Notably, selec-
tive blockade of β3-adrenoceptor activity by SR59230A
reverses the above effects causing a severe reduction of cancer
cell viability, which is sustained by increased mitochondrial
ROS. These results lead to the possibility of a selective antitu-
mor therapeutic use of β3-adrenoceptor blockade.
Redox state and signaling crucially impact on almost all
metabolic pathways. D-Tagatose is a sweetener, often found
in dairy products, as it is 92% as sweet, but with only 38%
of the calories of sucrose. Having shown a low glycation
potential in phase 3 clinical trial, it appears particularly
attractive for diabetic patients. Yet, no direct comparison
between D-tagatose and other sugars has been performed
so far. D. Collotta et al. compared for the first time the effect
of D-tagatose and fructose on lipid and sugar metabolism.
Using an in vivo approach, they found that fructose con-
sumption led to increased body weight and abnormal glu-
cose and lipid profile, associated with increased level of
oxidative markers. Conversely, chronic overconsumption of
D-tagatose in either liquid or solid formulation did not
exert the same deleterious metabolic derangements. Thus,
D-tagatose stands as a safer paradigm of sweeteners with lim-
ited toxicological impact on obesity and associated metabolic
disorders, prompting the initiation of clinical studies to
further confirm its safer metabolic profile in humans.
Another study by J. Gambardella et al. shows for the first
time that parathyroid hormone (PTH) determines endothe-
lial dysfunction in a ROS-dependent manner. This is partic-
ularly relevant as increased PTH activity is considered
among the possible mechanisms increasing cardiovascular
risk during vitamin D deficiency and in other pathological
conditions. ROS-induced oxidation of both bradykinin
receptor B2 and vascular endothelial growth factor (VEGF)
receptor 2 emerged as a major effect of PTH in endothelial
cells, likely resulting in impaired vasodilation and angiogen-
esis. The present work offers a novel and interesting model,
supporting a relevant role of PTH in inducing endothelial
dysfunction, which will need validation by in vivo experi-
ments and in the clinics.
Aldosterone also has cardiovascular effects. A. Cannavo
et al. reviewed the current knowledge concerning aldosterone
actions in the cardiovascular system and the most recent pre-
clinical studies and clinical trials designed to test better
approaches aimed at countering the hyperactivity of the
aldosterone/mineralocorticoid receptor signaling pathway
in the setting of cardiovascular diseases.
In another metabolic study, M. M. Rahman et al. investi-
gated the effect of loss of function of NADPH oxidase 2
(Nox2) on obesity-mediated alteration of bone remodeling
in wild-type (WT) and Nox2-knockout (KO) mice fed with
a standard lab chow diet (SD) as a control or a HFD as an
obesity model. Indeed, there is evidence supporting the role
of Nox in bone pathophysiology [15–18], and it is well
known that a high-fat diet (HFD) generates obesity, with
a negative impact on bone remodeling [19]. The authors
demonstrate that HFD enhances bone mineral density to
a greater extent in KO mice than in WT mice without
affecting the total body weight and fat mass. HFD also sig-
nificantly increases the number of adipocytes in the bone
marrow microenvironment of WT mice as compared to
KO mice. The bone levels of proinflammatory cytokines
and proosteoclastogenic factors were also enhanced in
WT-HFD compared to KO-HFD animals. Moreover, the
in vitro differentiation of bone marrow cells into osteoclasts
was significantly increased with bone marrow cells from
WT-HFD mice as compared to KO-HFD mice, pointing
towards Nox2 involvement in HFD-induced deleterious
bone remodeling by means of increased bone marrow adipo-
genesis and osteoclastogenesis.
The paper of H. Jiang et al. investigates another metabolic
condition, urolithiasis [20, 21], that is characterized by the
development of stony concretions in the bladder or urinary
tract. Solute carrier family 26 member 6 (Slc26a6), an impor-
tant oxalate transport, is expressed mainly in the apical mem-
brane of the intestine and kidneys. In this scenario, the
authors demonstrate that downregulation of Slc26a6 expres-
sion attenuated ROS production to reduce crystal formation.
Interestingly, in the setting of chronic kidney disease, D.
Cappetta et al. studied the inflammatory and oxidative
responses regulated by DPP4 in a model associated to cardio-
vascular dysfunction (Dahl salt-sensitive rats). Inhibition of
dipeptidyl peptidase 4 (DPP4) has emerged as a beneficial
strategy against chronic diseases including type 2 diabetes
and the related risk of kidney disease and other microvascu-
lar complications. In these settings, inflammation and
oxidative stress play a major role and are controlled by
DPP4 activity. In the kidney and many other organs, DPP4
degrades physiological substrates and is upregulated by
pathogenic signals [22–24]. In this context, selective and
chronic inhibition of DPP4 by sitagliptin reduced the
progression of renal dysfunction, ameliorated markers of
inflammation (reduced expression of NF-κB, TNFα, IL-1β,
IL-6, and MCP-1), induced macrophage polarization toward
the anti-inflammatory M2 phenotype, and decreased
NADPH oxidase 4 expression, oxidation of nucleic acids,
lipids, and proteins. The protective effect of this approach
supports the potential benefit of DPP4 inhibition in the
context of chronic multiorgan diseases.
Huge research efforts are focusing on therapeutic
strategies in respiratory diseases [25, 26]. A. G. Fois et al.
conducted a study on idiopathic pulmonary fibrosis (IPF), a
chronic lung disease characterized by enhanced fibrotic
response [27] that can eventually also lead to pulmonary
hypertension and right ventricular dysfunction [28, 29].
Molecular and cellular features characterizing the onset and
progression of this devastating disease are not clear yet, but
an aberrant remodeling of the pulmonary vasculature seems
to be involved [30]. The authors showed that enhanced
production of reactive oxygen species (ROS) induced by sera
from IPF patients drives both collagen type I deposition and
proliferation of primary human pulmonary artery smooth
muscle cells (HPASMCs). These effects were significantly
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inhibited in cells treated with the NADPH oxidase inhibitor
diphenyleneiodonium (DPI) proving the causative role of
ROS and suggesting their potential cellular source. On the
opposite, sera from IPF patients administered with pirfeni-
done did not increase ROS generation and collagen synthesis
in HPASMCs, suggesting that antioxidant properties are
involved in the in vivo effect of this molecule.
Finally, the review by E. Cianflone et al. summarizes our
current knowledge on the mechanisms potentially affecting
the regenerative potential of the aged heart [31, 32]. To what
extent these events are specific for the heart or could be trans-
posed to other organs, which similarly lose their regenerative
capacity during the postnatal life, will be an interesting topic
for future investigations.
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